Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2016

View Archived Issues

Medigene cleared to advance DC vaccine trial to phase II

Prous Institute announces new research collaboration agreement with Broad Institute

MIN-202 well tolerated and improves symptoms of depression in phase I study

First patient dosed in phase I trial of ADCT-402 in patients with B-NHL

Grant supports esophageal cancer screening study at Fred Hutchinson Cancer Research Center

FDA approves Xalkori for ROS1-positive metastatic NSCLC

Takeda Pharmaceutical patents HDAC6 inhibitors

Award supports Biosceptre's preclinical work in kidney and lung cancers

Astellas Pharma discloses muscarinic M3 receptor PAMs

EpiTherapeutics describes lysine-specific demethylase inhibitors

Sunnylife Pharma presents 5-HT2C receptor agonists

Oncology Venture initiates APO-010 screening study

University of Virginia reports RUNX1 inhibitors

First human data for HT-3951

BMS reports data on BMS-986142

AbbVie initiates phase III clinical studies to evaluate ABT-493/ABT-530

Efficacy of endoxifen in bipolar disorder

GNI submits IND to initiate clinical trials of F-351 for liver fibrosis

Roche launches DISCOVERY Yellow Kit

FDA approves Spectrum Pharmaceuticals' Evomela

Ozgene knock-in mouse model to help advance diabetes research at University of Auckland

MSD KK files application for approval of oral agents for chronic hepatitis C in Japan

FDA grants orphan drug designation to dianhydrogalacticol for the treatment of medulloblastoma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026